Tails of Innovation: Enhancing RNA Therapeutics via Novel Poly(A) Modifications

Presenters

Chunping Xu Ph.D.

Senior Director of Chemistry R&D

TriLink BioTechnologies

Bio

Close

Chunping Xu Ph.D.

Chunping Xu, PhD, is the Senior Director of Chemistry R&D at TriLink BioTechnologies, where she oversees the development of novel CleanCap® analogs for improved protein expression and process optimization for modified NTPs. In addition, she and her team are investigating how to increase mRNA stability with various chemical modifications. Leveraging expertise in nucleotide chemistry, Dr. Xu and her team have created a library of over 100 novel cap analogs to identify next-generation CleanCap® analogs. Before joining TriLink, she had extensive experience in small molecule drug development and conjugation.

Close

As the potential of mRNA-based medicines expands, researchers are making exciting strides in overcoming the challenges associated with the intrinsic instability and immunostimulatory properties of exogenous mRNA. By introducing various modifications through chemical or enzymatic methods across the entire mRNA sequence—from cap to tail—translational activity can be enhanced, and immunogenicity risks reduced. To that end, scientists at TriLink BioTechnologies have developed a novel modification to the poly(A) tail, which further improves the stability and translational activity of RNA therapeutics.

In this GEN Biotechnology webinar, Chunping Xu, PhD, will present results from experiments examining the impact of poly(A) tail modifications on mRNA longevity and protein translation. During the webinar, you’ll learn:

• The benefits of a tail modification to increase mRNA stability and longevity
• The impact of tail modifications on mRNA protein translation
• How to apply holistic strategies for mRNA optimization, from cap to tail

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.